-
1.发明授权SUBSTITUTED CARBAMOYLMETHYLAMINO ACETIC ACID DERIVATIVES AS NOVEL NEP INHIBITORS 有权作为新型NEP抑制剂的取代羧酰胺甲基氨基乙酸衍生物
公开(公告)号：EP2501683B1
公开(公告)日：2014-04-23
申请号：EP10781884.1
申请日：2010-11-18
申请人： Novartis AG
IPC分类号： C07D231/40 , C07D257/06 , C07D261/14 , A61K31/41 , A61K31/42 , A61K31/415 , A61P7/10
CPC分类号： A61K31/41 , A61K31/42 , A61K45/00 , C07D231/40 , C07D257/06 , C07D261/14
-
2.发明授权4-BENZYLAMINO-1-CARBOXYACYL-PIPERIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLIPIDEMIA OR ARTERIOSCLEROSIS 有权4-苄基氨基-1-羧酰基哌啶作为CETP抑制剂的治疗诸如高脂血症或动脉粥样硬化治疗
公开(公告)号：EP2207775B1
公开(公告)日：2012-03-21
申请号：EP08848438.1
申请日：2008-11-03
申请人： Novartis AG
发明人： MOGI, Muneto , YAMADA, Ken , YASOSHIMA, Kayo , KAWANAMI, Toshio , UMEMURA, Ichiro , IWAKI, Yuki , QIN, Hongbo , IMASE, Hidetomo
IPC分类号： C07D401/12 , C07D401/14 , C07D413/14 , A61K31/5377 , A61P3/06
CPC分类号： C07D401/14 , C07D413/14
摘要： The present invention provides a compound of formula (I): wherein the variants R1, R2, R3, R4, R5, R6, R7 are as defined herein, and wherein said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP.
-
3.发明授权1,2-DISUBSTITUTED-4-BENZYLAMINO-PYRROLIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLI PIDEMIA OR ARTERIOSCLEROSIS 有权1,2-二取代的4- BENZYLAMINOPYRROLIDINDERIVATE作为动脉硬化等疾病高脂血症或适合CETP抑制剂的治疗
公开(公告)号：EP2229356B1
公开(公告)日：2011-10-12
申请号：EP08857355.5
申请日：2008-12-01
申请人： Novartis AG
发明人： MOGI, Muneto , KAWANAMI, Toshio , YAMADA, Ken , YASOSHIMA, Kayo , IMASE, Hidetomo , MIYAKE, Takahiro , OHMORI, Osamu
IPC分类号： C07D207/14 , C07D403/12 , C07D403/14 , C07D401/14 , C07D405/14 , C07D413/14 , A61K31/40 , A61P3/06
CPC分类号： C07D207/14 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D413/14
摘要： The present invention provides a compound of formula (I): wherein the variants R1, R2, R3, R4, R6, R7 are as defined herein, and wherein said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP.
-
4.发明授权COMPLEMENT PATHWAY MODULATORS AND USES THEREOF 有权VERWENDUNGEN DAVON的MODULATOREN DES KOMPLEMENTWEGES
公开(公告)号：EP2855456B1
公开(公告)日：2017-03-29
申请号：EP13729096.1
申请日：2013-05-03
申请人： Novartis AG
发明人： ADAMS, Christopher Michael , BABU, Charles , DING, Jian , EHARA, Takeru , JENDZA, Keith , JI, Nan , KARKI, Rajeshri Ganesh , KAWANAMI, Toshio , XUE, Liang , MAINOLFI, Nello , POWERS, James J. , SERRANO-WU, Michael H. , ZHANG, Chun , CAPPARELLI, Michael Paul
IPC分类号： C07D403/06 , C07D413/06 , C07D417/06 , A61P27/02 , A61P37/00
CPC分类号： C07D403/06 , C07D413/06 , C07D417/06
-
公开(公告)号：EP2049517B1
公开(公告)日：2013-11-27
申请号：EP07786158.1
申请日：2007-07-18
申请人： Novartis AG
发明人： IMASE, Hidetomo , IWAKI, Yuki , KAWANAMI, Toshio , MIYAKE, Takahiro , MOGI, Muneto , OHMORI, Osamu , QIN, Hongbo , UMEMURA, Ichiro , YAMADA, Ken , YASOSHIMA, Kayo
IPC分类号： C07D401/12 , C07D311/30 , A61K31/455 , A61P9/00 , C07D211/58 , C07D401/14 , C07D413/14 , C07D417/14
CPC分类号： C07D211/58 , C07D401/12 , C07D401/14 , C07D413/14 , C07D417/14
-
6.发明授权2-(1H-INDOL-4-YLMETHYL)-3H-IMIDAZO[4,5-B]PYRIDINE-6-CARBONITRILE DERIVATIVES AS COMPLEMENT FACTOR B INHIBITORS USEFUL FOR THE TREATMENT OF OPHTHALMIC DISEASES 有权2-（1H-吲哚-4-基甲基）-3H-咪唑并[4,5-B]对于眼科疾病的治疗中有用的吡啶-6-甲腈衍生物作为补体因子B抑制剂
公开(公告)号：EP2970269B1
公开(公告)日：2017-04-19
申请号：EP14719470.8
申请日：2014-03-13
申请人： Novartis AG
发明人： ADAMS, Christopher Michael , BABU, Charles , CAPPARELLI, Michael Paul , DING, Jian , EHARA, Takeru , JENDZA, Keith , JI, Nan , KARKI, Rajeshri Ganesh , KAWANAMI, Toshio , MAINOLFI, Nello , POWERS, James J. , SERRANO-WU, Michael H. , XUE, Liang , ZHANG, Chun
IPC分类号： C07D471/04 , A61K31/437 , A61P27/02
CPC分类号： C07D471/04
-
7.发明公开TETRAHYDROPYRIDO-PYRIDINE AND TETRAHYDROPYRIDO-PYRIMIDINE COMPOUNDS AND USE THEREOF AS C5A RECEPTOR MODULATORS 有权四氢吡啶 - 吡啶和四氢吡啶 - 嘧啶化合物及其用作C5A受体调节剂的用途
公开(公告)号：EP2734521A1
公开(公告)日：2014-05-28
申请号：EP12743023.9
申请日：2012-07-20
申请人： Novartis AG
发明人： GELIN, Christine , FLYER, Alec , ADAMS, Christopher, Michael , DARSIGNY, Veronique , HURLEY, Timothy, Brian , KARKI, Rajeshri, Ganesh , JI, Nan , KAWANAMI, Toshio , MEREDITH, Erik , SERRANO-WU, Michael, H. , RAO, Chang , SOLOVAY, Catherine , LEE, George, Tien-san , TOWLER, Christopher , HAR, Denis , SHEN, Lichun , HU, Bin , JIANG, Xinglong , CAPPACI-DANIEL, Christina
IPC分类号： C07D471/04 , A61K31/4375 , A61K31/519 , A61P27/02 , A61P37/00
CPC分类号： C07D471/04 , C07D471/08 , C07D471/10 , C07D491/044 , C07D491/107
摘要： The present invention provides a compound of formula I: (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
摘要翻译： 本发明提供了式I化合物：（I）制备本发明化合物的方法及其治疗用途。 本发明进一步提供药理活性剂和药物组合物的组合。
-
8.发明公开
公开(公告)号：EP2435409A1
公开(公告)日：2012-04-04
申请号：EP10720165.9
申请日：2010-05-26
申请人： Novartis AG
发明人： COPPOLA, Gary Mark , IWAKI, Yuki , KARKI, Rajeshri Ganesh , KAWANAMI, Toshio , KSANDER, Gary Michael , MOGI, Muneto , SUN, Robert
IPC分类号： C07D213/82 , C07D239/36 , C07D261/18 , C07D271/06 , C07C233/47 , A61K31/21 , A61K31/435
CPC分类号： C07D317/34 , A61K31/197 , A61K31/216 , A61K31/325 , A61K31/351 , A61K31/357 , A61K31/41 , A61K31/421 , A61K31/44 , A61K31/505 , A61K31/5375 , A61K45/00 , A61K45/06 , C07B2200/05 , C07C233/47 , C07C233/49 , C07C233/51 , C07C233/56 , C07C233/63 , C07C235/12 , C07C235/78 , C07C237/16 , C07C237/22 , C07C255/60 , C07C271/22 , C07C275/24 , C07C311/08 , C07C311/51 , C07C2601/08 , C07C2601/14 , C07C2602/08 , C07D213/82 , C07D239/28 , C07D239/34 , C07D239/36 , C07D257/04 , C07D261/18 , C07D263/32 , C07D265/30 , C07D271/06 , C07D295/15 , C07D309/32
摘要： The present invention provides a compound of formula I' or a pharmaceutically acceptable salt thereof, wherein R
1 , R
2 , R
3 , R
5 , B
1 , X and n are defined herein. The invention also relates a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.摘要翻译： 本发明提供了式I'化合物或其药学上可接受的盐，其中R 1，R 2，R 3，R 5，B 1，X和n如本文所定义。 本发明还涉及制造本发明化合物的方法及其治疗用途。 本发明进一步提供药理活性剂和药物组合物的组合。
-
9.发明公开1,2-DISUBSTITUTED-4-BENZYLAMINO-PYRROLIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLI PIDEMIA OR ARTERIOSCLEROSIS 有权1,2-二取代的4- BENZYLAMINOPYRROLIDINDERIVATE作为动脉硬化等疾病高脂血症或适合CETP抑制剂的治疗
公开(公告)号：EP2229356A1
公开(公告)日：2010-09-22
申请号：EP08857355.5
申请日：2008-12-01
申请人： Novartis AG
发明人： MOGI, Muneto , KAWANAMI, Toshio , YAMADA, Ken , YASOSHIMA, Kayo , IMASE, Hidetomo , MIYAKE, Takahiro , OHMORI, Osamu
IPC分类号： C07D207/14 , C07D403/12 , C07D403/14 , C07D401/14 , C07D405/14 , C07D413/14 , A61K31/40 , A61P3/06
CPC分类号： C07D207/14 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D413/14
摘要： The present invention provides a compound of formula (I): wherein the variants R1, R2, R3, R4, R6, R7 are as defined herein, and wherein said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP.
-
10.发明授权
公开(公告)号：EP2734521B1
公开(公告)日：2017-05-10
申请号：EP12743023.9
申请日：2012-07-20
申请人： Novartis AG
发明人： GELIN, Christine , FLYER, Alec , ADAMS, Christopher, Michael , DARSIGNY, Veronique , HURLEY, Timothy, Brian , KARKI, Rajeshri, Ganesh , JI, Nan , KAWANAMI, Toshio , MEREDITH, Erik , SERRANO-WU, Michael, H. , RAO, Chang , SOLOVAY, Catherine , LEE, George, Tien-san , TOWLER, Christopher , HAR, Denis , SHEN, Lichun , HU, Bin , JIANG, Xinglong , CAPPACI-DANIEL, Christina
IPC分类号： C07D471/04 , A61K31/4375 , A61K31/519 , A61P27/02 , A61P37/00
CPC分类号： C07D471/04 , C07D471/08 , C07D471/10 , C07D491/044 , C07D491/107
-
-
-
-
-
-
-
-
-
搜索结果
20 条记录 (耗时 0.038 秒)
